Aquapass has secured marketing approval in Israel for the AQUAPASS System, intended for patients experiencing fluid overload.

The approval allows the medical technology company to commence commercial deployment in selected medical centres across the country, with plans to gather clinical feedback and generate real-world evidence to support broader adoption.

It is said to cover clinical indications, including nephrology, cardiology, and general medicine, and supports use in both acute and chronic patients.